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REVIEW
Abstract: Acute exacerbations of COPD can complicate the course of the disease in patients 
with severe airway obstruction. Reduction of exacerbations is an important clinical outcome 
in evaluating new therapies in COPD. Combination therapies with long-acting ß-agonists and 
inhaled corticosteroids have now been approved for use. Three 1-year randomized clinical trials, 
which studied the effect of combining a long-acting ß2-agonist with an inhaled corticosteroid 
in COPD, documented that exacerbation frequency was lower with therapy than placebo. 
Combination therapy had a similar effect to its monocomponents in the trial evaluating salm-
eterol/ﬂ  uticasone combination. However, when patients with more severe COPD were studied 
using a combination of budesonide and formoterol, a clear improvement was seen in the overall 
exacerbation rates compared with the use of a long-acting ß2-agonist alone.
Keywords: COPD, exacerbation, inhaled corticosteroids, inhaled long-acting ß2-agonists, 
budesonide, ﬂ  uticasone, formoterol, salmeterol, combination therapy
Introduction
Acute exacerbations of COPD are characterized by a change in cough, sputum 
production, and respiratory symptoms from baseline that cause the patient to seek 
medical attention and involve increasing the dose and/or frequency of existing 
bronchodilator therapy. Systemic corticosteroids are also recommended in patients 
with more advanced COPD that may require hospitalization. Exacerbations may 
be mild, necessitating only outpatient therapy such as antibiotics and/or systemic 
steroids but often may be severe enough to require hospitalization and admission 
to the intensive care unit. Therefore, prevention of exacerbations is one of the most 
important goals of chronic obstructive pulmonary disease (COPD) management 
(Global Initiative for Chronic Obstructive Lung Disease 2005) because of the impact 
on patients’ daily activities and health-related quality of life (HRQoL), with these 
effects lasting for several weeks or months (Haughney and Gruffydd-Jones 2004). 
Frequent exacerbations also lead to a poorer recovery in terms of improvement in 
health status (Haughney and Gruffydd-Jones 2004). Furthermore, the frequency of 
acute exacerbation has a signiﬁ  cant impact on the accelerated decline of lung function 
(Donaldson et al 2002) and also on healthcare costs (Haughney and Gruffydd-Jones 
2004). Consequently, strategies for preventing COPD exacerbations may have an 
important effect on the natural course, cost of management, and mortality in COPD 
(Martinez and Anzueto 2005). 
In recent years, several large-scale clinical trials in COPD have analyzed the 
exacerbation-preventing aspects of different treatments (Niewoehner 2004; Solèr 
2005). These include inhaled bronchodilators, inhaled corticosteroids (ICSs), and a 
limited number of antimicrobial strategies. However, most antimicrobial strategies 
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have been used therapeutically in the form of antibiotic 
treatment during an established exacerbation, apart from 
vaccinations against inﬂ  uenza and pneumococci, which 
can protect from these infections which are particularly 
dangerous for COPD patients (Cazzola et al 2005).
Effect of long-acting ß2-agonists 
and inhaled corticosteroid in 
preventing COPD exacerbations
Long-acting ß2-agonists (LABAs) have both bronchodilator 
and non-bronchodilator properties, whereas ICSs are potent 
anti-inﬂ  ammatory agents (Cazzola and Dahl 2004). It is, 
therefore, obvious that LABAs and ICSs treat different 
aspects of COPD (Cazzola and Dahl 2004). LABAs are 
central in the symptomatic control of COPD (American 
Thoracic Society/European Respiratory Society 2005), 
whereas conﬂ  icting results have been reported with ICSs 
(Barnes 2000; Calverley 2000). This may reﬂ  ect the fact 
that the inﬂ  ammation in COPD is poorly suppressed by 
corticosteroids, with small reduction in inﬂ  ammatory cells, 
cytokines, or proteases in induced sputum even with oral 
corticosteroids (Barnes 2004), although there are some sub-
groups of patients (eg, those with eosinophilia) who respond 
very well (Chanez et al 1997).
Nonetheless, findings from several clinical studies 
have shown that treatment with ICSs improve expiratory 
airﬂ  ow and reduce symptoms and the rate of exacerbations 
associated with COPD (Alsaeedi et al 2002), and, moreover, 
reduce all-cause mortality in COPD (Sin et al 2005). ICSs 
in relatively high doses (eg, budesonide 800 μg/day or 
ﬂ  uticasone propionate 1 mg/day) reduce exacerbations by 
20%–30% and improve the health status of COPD patients 
by a similar amount compared with placebo (Man and Sin 
2005). In particular, a meta-analysis of six trials, which 
evaluated the long-term effects (≥6 months) of ICSs in stable 
COPD and provided information about total exacerbations, 
demonstrated that ICSs reduce exacerbation rates in COPD 
by nearly one third relative to placebo (relative risk [RR], 
0.70; 95% CI, 0.58–0.84) (Alsaeedi et al 2002). In the 
ISOLDE (Inhaled Steroid in Obstructive Lung Disease 
in Europe) study, the major beneﬁ  t of therapy was seen 
in those whose lung function was less than 50% of pre-
dicted; however, the number of patients having at least one 
exacerbation per year was reduced with ICSs irrespective 
of baseline lung function (Jones et al 2003). A convincing 
demonstration of the effectiveness of these agents in COPD 
patients has come from the COPE study (an investigation 
of COPD in the Department of Pulmonology,
 Enschede, the 
Netherlands) (van der Valk et al 2002). This study showed 
that the discontinuation of therapy with ICSs was associated 
with a more rapid onset and a higher risk of recurrence of 
exacerbations, and with a
 signiﬁ  cant deterioration in aspects 
of HRQoL, in the majority of patients. However, 40% of 
subjects in the COPE study experienced no untoward effect 
from the withdrawal
 of ICSs. This ﬁ  nding indicates that there 
is an urgent need to identify which subgroups of COPD 
patients respond well to prolonged ICSs therapy. In any case, 
a recent article that has reviewed the diverse approaches to 
data analysis used in the randomized trials of ICSs in the 
treatment of COPD and their meta-analysis, has concluded 
that the reports that ICSs reduce COPD exacerbation rates are 
the result of improper statistical analysis techniques (Suissa 
2006). The only two studies that used the correct statistical 
approach found insigniﬁ  cant effects with these drugs. It is 
not a surprise, therefore, that the evaluation of a cohort of 
newly treated COPD patients formed from the Administrative 
Databases of Saskatchewan Health documented that ICSs 
do not seem to be beneﬁ  cial in preventing the risk of a ﬁ  rst 
exacerbation of COPD (de Melo et al 2004). Interestingly, 
a recent paper has documented that immortal
 time bias 
cannot account for the risk reduction associated with
 ICSs 
exposure in observational studies (Kiri et al 2005). This 
ﬁ  nding is strengthened by the observed relationship
 between 
increased regularity of ICSs prescriptions and reductions
 in 
event rates.
Although LABAs have been shown to reduce exacerba-
tion rates of COPD, the magnitude of the effect appears 
modest at best. Published trials reveal that salmeterol is 
the only LABA with a signiﬁ  cant effect on the rate of 
exacerbations. In a 1-year study comparing salmeterol 
with placebo, salmeterol signiﬁ  cantly reduced the mean 
number of exacerbations per patient by 20% and the mean 
number of exacerbations requiring oral corticosteroids 
per patient by 29% (Calverley et al 2003a). Recently, it 
has been documented that the addition of salmeterol to 
existing treatment in patients with a history of COPD 
exacerbations and poor reversibility of airﬂ  ow obstruction 
reduces exacerbations in patients who comply with treat-
ment (Stockley et al 2006). On the contrary, formoterol, 
in twice daily doses, failed to show such an effect in two 
other trials (Calverley et al 2003b; Szafranski et al 2003), 
although a subsequent study has documented that it can 
inﬂ  uence exacerbation surrogates, for example “bad days” 
(Dahl et al 2002). Salmeterol has been shown in several 
model systems to reduce inﬂ  ammatory cell activation, International Journal of COPD 2006:1(4) 347
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to reduce formation of edema and to enhance edema 
clearance, and to mitigate epithelial damage induced 
by bacteria (Rennard 2004). Whether these effects have 
any clinical importance remains to be determined, but 
they may account for its ability to reduce frequency of 
exacerbations of COPD. Formoterol may have similar 
non-bronchodilator effects; however, studies are needed 
to document these effects.
Pharmacological rationale for 
combining long-acting ß2-agonists 
and inhaled corticosteroid in 
COPD
Interaction at the molecular level 
between ICSs and LABAs
Combining two therapies that possess different modes of 
action could be expected to have a greater beneﬁ  t in the 
management of COPD. There is an exciting possibility 
that the potential beneﬁ  t in combining ICSs and LABAs 
might be due to a synergistic interaction. However, the 
basic molecular mechanism of such an interaction has still 
to be fully identiﬁ  ed. Recent in vitro and in vivo evidence 
suggest a mechanistic interaction at the molecular level be-
tween ICSs and LABAs. Corticosteroids have been shown 
to up-regulate the ß2-adrenoceptor in the human airways, 
which in turn may provide more receptors for ß2-agonists to 
activate (Mak et al 1995; Baraniuk et al 1997). At the same 
time, LABAs may potentiate the molecular mechanism of 
corticosteroid actions by increasing the nuclear transloca-
tion of glucocorticoid receptors (GRs) and thus causing an 
additive or sometimes synergistic suppression of inﬂ  am-
matory mediator release (Eickelberg et al 1999; Korn et al 
2001; Pang and Knox 2000, 2001). Similar interactions 
between ICSs and LABAs in vivo are a likely explanation 
for the effects seen in the study of Barnes and coworkers 
(2006) documenting that the combination of inhaled sal-
meterol and ﬂ  uticasone propionate signiﬁ  cantly reduced 
the absolute numbers of biopsy (CD45
+) leukocytes, CD8
+ 
cells, and CD4
+ cells together with decreases in cells ex-
pressing genes for the proinﬂ  ammatory mediators IFN-γ 
and TNF-α. In the complementary airway compartment 
sampled by induced sputum, combination treatment sig-
niﬁ  cantly reduced sputum differential neutrophils and total 
eosinophils. Furthermore, in vitro studies suggest that the 
addition of a LABA to an ICS may counter some of the 
potential negative effects of the corticosteroid (Tse et al 
2003) or alternatively, some of those elicited by LABA 
(Seeto et al 2003).
Increasing compliance
In addition to the complementary interaction of LABAs and 
ICSs at the molecular level, the delivery of these medications 
together in a single device may also help simplify treatment 
regimens and improve patient adherence (Cazzola and Dahl 
2004). It is widely recognized that adherence to treatment of 
chronic obstructive airways diseases declines as the regime 
becomes more complicated, either by increasing the number 
of medications and/or the number of daily doses (Coutts 
et al 1992; Chapman et al 2000). As a result, improved 
compliance would be expected to occur through the use of 
a single combination inhaler simply because of the reduc-
tion in the number of medications and actuations required 
with such a regime. In particular, it would be expected that 
the use of combination therapy should improve compliance 
with ICS therapy as its use is linked with LABA therapy, 
which patients are more likely to take because of the greater 
symptomatic beneﬁ  t.
Enhanced respiratory cytoprotection 
against viral and bacterial
 infection
Because of the above effects, it is not unexpected that 
long-term use of ICSs with LABAs may be associated with 
a reduction in COPD exacerbations (Cazzola and Dahl 
2004). However, the capacity of both ICSs and LABAs to 
reduce the total number of bacteria adhering to the respira-
tory mucosa in a concentration-dependent manner without 
altering the bacterial tropism for mucosa, and to preserve 
ciliated cells, is important in this context (Dowling et al 
1999). ICSs and LABAs, when administered together at 
low concentrations, exhibited a synergistic effect with 
respect to the preservation of ciliated cells, showing a trend 
toward reduced damage and a signiﬁ  cant preservation of the 
number of ciliated cells compared with either agent alone 
at the same concentrations. This result may have clinical 
signiﬁ  cance as it is thought that ciliated cells are the most 
sensitive to damage by bacterial infection (Tsang et al 1994). 
It is well-known that airway colonization and chronic infec-
tion contribute to progressive pulmonary damage in COPD 
patients via the action of proinﬂ  ammatory substances in 
what is known as the “vicious circle theory” (Wilson 1991). 
Recently, the synergistic effects of salmeterol and ﬂ  utica-
sone in human rhinovirus-induced proinﬂ  ammatory cytokine 
production have also been documented (Edwards et al 2006). International Journal of COPD 2006:1(4) 348
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Rhinoviruses are implicated in many acute exacerbations 
of COPD, perhaps by inducing proinﬂ  ammatory cytokines 
(Seemungal et al 2001).
Effect of combination therapy in 
preventing COPD exacerbations
The efﬁ  cacy of combination therapy with ICSs and LABAs 
delivered via a single inhaler to COPD patients has repeatedly 
been documented (Table 1). In particular, the impact on acute 
exacerbations of long-term treatments with combined therapy 
is shown in Figures 1 and 2, and Table 2. It is very important 
to also mention that the deﬁ  nition of exacerbation and the 
patient population enrolled in these studies are not uniform 
(Table 3), and these facts have to be taken in consideration 
when analyzing their results.
In a multicenter, randomized, placebo-controlled study, 
Hanania et al (2003) compared the efﬁ  cacy and safety of 
fluticasone propionate (250 μg) and salmeterol (50 μg), 
when administered twice daily together in a single device 
for 6 months, with that of placebo and the individual agents 
alone in patients with COPD. This study was unable to ob-
serve signiﬁ  cant differences among treatment groups in the 
number of exacerbations or the time to ﬁ  rst exacerbation. 
However, this study was of short duration and was designed 
and powered to evaluate the treatment effect on FEV1, which 
was the primary measure of efﬁ  cacy, rather than to evaluate 
the rates of exacerbations.
In a study with a similar design but evaluating the 
higher dose formulation of this combination therapy, 
ﬂ  uticasone propionate (500 μg) with salmeterol (50 μg) 
twice daily given for 6 months (Mahler et al 2002), there 
were no statistically significant differences between 
treatment groups in time to exacerbation. This study also 
demonstrated no difference in the number of participants 
who exacerbated once (placebo: 8.8%; salmeterol: 5.6%; 
fluticasone: 10.1%; fluticase/salmeterol combination 
[FSC]: 8.5%), but no p values were presented. Also this 
study was of short duration and was designed and powered 
to evaluate the treatment effect on FEV1, which was the 
primary measure of efﬁ  cacy, rather than to evaluate the 
rates of exacerbations.
The TRISTAN study (Calverley et al 2003a), a 
randomized controlled trial over 1 year of combination 
treatment with salmeterol (50 μg) and ﬂ  uticasone (500 μg) 
administered together in a single device twice daily versus 
each of the components alone and versus placebo, enrolled 
patients with a baseline FEV1 before bronchodilation that 
was 25%–70% of that predicted. In this study, the rate of 
exacerbations requiring medical intervention, deﬁ  ned as 
a worsening of COPD symptoms that required treatment 
with antibiotics or oral corticosteroids, or both, fell by 
25% in the combination group and by 20% and 19% in the 
salmeterol and ﬂ  uticasone groups, respectively, compared 
with placebo. In particular, there was a significant 
difference in the mean exacerbation rate per participant per 
year in favor of the combination therapy when compared 
with placebo (FSC: 0.97 vs placebo: 1.30, p<0.0001), but, 
interestingly, differences among the three active treatment 
arms were small and not statistically signiﬁ  cant. The 
treatment effect was more pronounced in patients with 
severe disease (ie, a baseline FEV1 <50% of predicted), 
who showed a 30% reduction with combination therapy 
compared with placebo, compared with a 10% reduction 
in patients who had a baseline FEV1 greater than 50% of 
predicted. However, this beneﬁ  cial effect was also seen 
for exacerbations treated with oral corticosteroids, which 
have conventionally been thought to be more severe 
episodes. The combination therapy was associated with 
an approximate 39% reduction in the number of this type 
of exacerbations compared with placebo (0.46 vs 0.76 
exacerbations per year, p<0.0001) but, again, the differ-
ences between FSC and salmeterol or ﬂ  uticasone were 
not signiﬁ  cant. It is worth mentioning that the TRISTAN 
was longer, but still based on FEV1. Hence, the ability to 
observe exacerbation differences may have been helped 
by study duration.
In a study using a design similar to that of the TRISTAN 
study but including patients with an FEV1 below 50% 
predicted, Szafranski et al (2003) compared the effects of 
two inhalations twice daily of either budesonide/formoterol 
combination (BFC) 160/4.5 μg (delivered dose) in a single 
inhaler, budesonide 200 μg (metered dose), formoterol 4.5 μg, 
or placebo for 12 months. Data from this study demonstrate 
a signiﬁ  cant reduction in the number of severe exacerbations 
by 24% in the BFC group vs placebo, 23% vs formoterol, 
and 11% vs budesonide. This reﬂ  ects a mean reduction in the 
mean annual exacerbation rates of 0.42 (95% CI 0.14–0.70), 
1.84–1.42 exacerbations per year when combination therapy 
was used. Compared with placebo, both BFC and budesonide 
signiﬁ  cantly reduced the number of oral steroid courses 
used in association with exacerbations (31% and 29%, 
respectively, compared with 3% for formoterol vs placebo). 
In addition, BFC signiﬁ  cantly reduced the number of oral 
steroid courses compared with formoterol (–28%). Mild 
exacerbations were also signiﬁ  cantly reduced on BFC when International Journal of COPD 2006:1(4) 349
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compared with placebo (–62%) and budesonide (–35%), but 
not with formoterol (–15%).
In another study investigating BFC, Calverley 
et al (2003b) studied patients who initially received 
formoterol alone (9 μg delivered dose twice daily) and 
a short course of oral prednisolone (30 mg once daily) 
for 2 weeks before randomization. The patients were 
subsequently randomized to twice daily inhaled BFC 
320/9 μg (delivered dose), budesonide 400 μg (metered 
dose), formoterol 9 μg, or placebo for 12 months, BFC 
prolonged time to ﬁ  rst exacerbation requiring medical 
intervention, defined as a need for antibiotics and/or 
oral corticosteroids and/or hospitalization due to 
respiratory symptoms, compared with all other treatments. 
Hazard rate analysis showed that the risk of having an 
exacerbation while being treated with BFC was reduced 
by 22.7%, 29.5%, and 28.5% vs budesonide, formoterol, 
and placebo, respectively. The exacerbation rate with 
BFC was reduced compared with placebo (23.6%) and 
formoterol (25.5%) but not with budesonide alone 
(13.6%). Neither budesonide nor formoterol affected 
either measure of exacerbation compared with placebo. 
Furthermore, BFC prolonged the time to ﬁ  rst course of 
oral corticosteroids after randomization; risk reductions 
were 32.7% and 33.8% vs budesonide and formoterol, 
respectively, and 42.3% vs placebo. BFC also reduced 
the rate of oral corticosteroid courses by 28.2%, 30.5%, 
and 44.7% vs budesonide, formoterol, and placebo, 
respectively; budesonide alone reduced the number of 
oral corticosteroid courses compared with placebo but 
formoterol did not.
Considerations on the role of the 
combination therapy in preventing 
COPD exacerbations
Data of three large studies (Calverley et al 2003a, 2003b; 
Szafranski et al 2003) that have examined the effects of 
a combination of LABA and ICS on the risk of develop-
ing exacerbation in COPD have shown that the patients 
receiving combination therapy were less likely to report 
an exacerbation than those receiving the LABA alone. 
Nevertheless, a recent Cochrane review (Nannini et al 
2004) concluded that there were conﬂ  icting results when 
the different combination therapies were compared with 
the single components alone. In particular, the results 
of the studies showed that BFC and FSC were effective 
and reduced the frequency of exacerbations compared 
Table 1 Long-term effect of combination therapy in COPD
  Study   Treatment   N   Duration   Baseline    Primary 
 (µg  bid)
a     (weeks)   FEV1  (% pred)   outcome(s) 
Fluticasone/salmeterol (FSC) 
Hanania et al 2003   FSC  250/50   178   24   41%   Changes  in  FEV1 
 FP  250   183     42% 
 SAL  50   177     42% 
 PLA   185     42%   
Mahler et al 2002   FSC  500/50   165   24   41%   Changes  in  FEV1 
 FP  500   168     41% 
 SAL  50   160     40% 
 PLA   181     41%   
Calverley et al 2003a   FSC 500/50   358   52   45%   Changes  in  FEV1 
(TRISTAN study)    FP  500   374     45% 
 SAL  50   372     44% 
 PLA   361     44.2   
Budesonide/formoterol (BFC) 
Szafranski et al 2003    BFC  400/12   208   52   36%   Changes  in  FEV1   
 BUD  400   198     37% 
 FORM  12   201     36% 
 PLA   205     36%    Number of exacerbations 
Calverley et al 2003b   BFC  400/12   254   52   36%   Changes  in  FEV1  
 BUD  400   257     36% 
 FORM  12   255     36% 
 PLA   256     36%    Time to ﬁ  rst exacerbation 
a All doses are reported as metered doses.
Abbreviations: BFC, budesonide/formoterol combination; BUD, budesonide; FORM, formoterol; FP, ﬂ  uticasone propionate; FSC, ﬂ  uticasone/salmeterol combination; 
PLA, placebo; SAL, salmeterol. International Journal of COPD 2006:1(4) 350
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with dummy medication to a level of three quarters of 
the previous rates, with one exacerbation prevented every 
2–4 years in the participants in the clinical trials. When 
the combination treatment was compared with one of the 
component drugs given as single treatments, BFC was bet-
ter than its component LABA at preventing the frequency 
of exacerbations, but FSC did not show a significant 
advantage over LABA. Recently, two different reviews 
(Halpin 2005; Cazzola 2006), which have evaluated the 
applicability and clinical relevance of number needed to 
treat (NNT) analysis for determining the effectiveness of 
combination therapies against COPD exacerbations, have 
calculated that for every 100 patients treated with BFC for 
1 year, between 42 and 47 exacerbations requiring medical 
intervention would be prevented vs LABA therapy alone, 
whereas for every 100 patients treated with FSC for 1 year, 
only 7 exacerbations would be prevented vs LABA alone 
(Table 2). It should be noted, however, that the NNT value 
relating to FSC should be interpreted with caution as there 
was no signiﬁ  cant difference between FSC and salmeterol 
alone (p=0.345 for treatment ratios for combination vs 
salmeterol therapy). This means that the hypothetical 95% 
CI would include inﬁ  nity and that an NNT of inﬁ  nity should 
be more appropriately applied to the difference between the 
two treatments, which indicates no true net clinical beneﬁ  t 
of FSC over salmeterol alone.
In any case, in a recent study investigating the effect 
withdrawal of ﬂ  uticasone from patients with severe COPD 
(FEV1 <50% predicted) using FSC (COSMIC study) for 
3 months, Wouters et al (2005) demonstrated an acute and 
sustained decrease in FEV1, increase in symptoms, and 
an increase in mild exacerbations in patients treated with 
salmeterol alone compared with those who continued treat-
ment with FSC over the one year of the study. These results 
emphasize the key role of ICSs in managing COPD.
The conflicting findings between the results of 
the different studies may be accounted for by dis-
similar study designs. In particular, deﬁ  nitions of ex-
acerbation that have been used in the examined studies 
have been rather different (Table 3). For example, in 
Mahler’s study (Mahler et al 2002), exacerbation was 
deﬁ  ned by treatment (mild = increased use of salbuta-
mol; moderate = use of either oral antibiotics and/or 
corticosteroids; severe = hospitalization). In the Szafran-
ski’s study (Szafranski et al 2003), the deﬁ  nition of mild 
exacerbation was a day with ≥4 inhalations of reliever 
medication above the mean run-in use, whereas that of 
severe exacerbation was a requirement for oral steroids 
and/or antibiotics and/or hospitalization due to respira-
tory symptoms. In the TRISTAN study (Calverley et al 
2003a), exacerbations were deﬁ  ned a priori as a worsening 
of COPD symptoms that required treatment with antibiot-
ics or oral corticosteroids, or both. Episodes that required 
corticosteroid treatment or hospital admission were noted 
separately. Pauwels et al (2004) correctly highlighted that 
considerable heterogeneity in the aetiology and manifes-
tation of COPD exacerbations makes identiﬁ  cation and 
quantiﬁ  cation of deﬁ  ning symptoms extremely difﬁ  cult. 
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Figure 1 Total severe exacerbation rate. 
Notes: PLA, placebo; LABA, salmeterol 50 µg bid or formoterol 12 µg bid; ICS, ﬂ  uticasone propionate 500 µg bid or budesonide 400 µg bid; LABA/ICS, salmeterol 50 µg/
ﬂ  uticasone 500 µg bid or formoterol 12 µg/budesonide 400 µg bid. * difference between combination treatment and single compound treatment and/or PLA statistically 
signiﬁ  cant (p<0.05); § difference between single compound treatment and PLA statistically signiﬁ  cant (p<0.05). Data from Calverley et al 2003a (TRISTAN); Calverley et al 
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However, with the emergence of a number of drugs 
designed or developed speciﬁ  cally to treat COPD and as-
sociated exacerbations, the absence of a uniform deﬁ  nition 
is a signiﬁ  cant issue. In fact, the choice of deﬁ  nition can 
signiﬁ  cantly affect study outcomes, with varying criteria 
likely to result in different levels of demonstrated treat-
ment success. Furthermore, emerging data conﬁ  rm that 
exacerbation is a term not easily understood by patients, 
who prefer to use simpler words such as “crisis” (Haughney 
and Gruffydd-Jones 2004).
It is also interesting to stress that there was some 
difference in the patient populations enrolled in the studies 
described above. Patients enrolled in the TRISTAN study 
(Calverley et al 2003a) had to have suffered from at least 
one episode of acute COPD symptom exacerbation per 
year in the previous 3 years, and at least one exacerbation 
in the year immediately before trial entry that required 
treatment with oral corticosteroids, antibiotics, or both. In the 
Szafranski study (Szafranski et al 2003), patients had to have 
suffered from at least one severe (use of oral corticosteroids 
and/or antibiotics and/or hospitalization due to respiratory 
symptoms) COPD exacerbation within 2±12 months before 
the ﬁ  rst clinic visit. Moreover, the mean pre-trial FEV1 was 
45% predicted in the TRISTAN study (Calverley et al 2003a) 
and 36% predicted in the Szafranski’s study (Szafranski 
et al 2003). Moreover, the mean total exacerbation rate per 
patient per year under placebo was 1.30 in the TRISTAN 
study (Calverley et al 2003a) and 1.9 in the Szafranski 
study (Szafranski et al 2003). This differences indicate that 
the Szafranski’s study (Szafranski et al 2003) probably 
enrolled patients with more severe disease or, at least, with 
a higher possibility of suffering from acute exacerbation. In 
fact, also in the Calverley study (Calverley et al 2003b), the 
mean pre-trial FEV1 was 36% predicted and the mean total 
exacerbation rate per patient per year under placebo was 
1.80. As correctly highlighted by Calverley et al (2003b), the 
more severe disease in the patients enrolled in BFC studies 
is the likely explanation of the greater number of episodes 
that they observed compared with other studies, a difference 
that increased the power of the study to detect an effect of 
treatment. It is also important to highlight that the authors 
of the three studies did not report the number of exacerba-
tions in the year before the enrolment in the studies. This is 
a real lack of information because, as recently documented 
by Donaldson et al (2003), annual exacerbation frequency 
remains constant over time.
As Rabe (2003) stated in his editorial comment on the 
Calverley paper (Calverley et al 2003b), the data of the 
combination therapy trials in COPD seem to indicate that 
patients experiencing more severe exacerbations beneﬁ  t the 
most from combination therapy, whereas, if the deﬁ  nition 
of a (mild) exacerbation for clinical trials also includes ag-
gravation of symptoms, such as in the paper by Szafranski 
et al (2003), the relative effect of a long-acting bronchodila-
tor might be more pronounced. This clearly highlights the 
importance of deﬁ  nitions of exacerbations for clinical trials 
and calls for studies comparing the effect of maximal bron-
chodilation with, for example, the combination of LABAs 
Figure 2 Rate of exacerbations requiring oral corticosteroids.
Notes: PLA, placebo; LABA, salmeterol 50 µg bid or formoterol 12 µg bid; ICS, ﬂ  uticasone propionate 500 µg bid or budesonide 400 µg bid; LABA/ICS, salmeterol 50 µg/
ﬂ  uticasone 500 µg bid or formoterol 12 µg/budesonide 400 µg bid. * difference between combination treatment and single compound treatment and/or PLA statistically 
signiﬁ  cant (p<0.05); § difference between single compound treatment and PLA statistically signiﬁ  cant (p<0.05). Data from Calverley et al 2003a (TRISTAN); Calverley et al 
2003b; Szafranski et al 2003.
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with long-acting anticholinergics (LAMAs) in COPD with 
mild and severe exacerbations as an outcome. In effect, some 
studies are documenting the clinical value of combining a 
LABA with a LAMA in COPD (Cazzola et al 2004; van 
Noord et al 2005, 2006), although the information of the 
impact of such a type of combination on exacerbations is 
still lacking.
Borrowing Jones’ opinion (Jones 2004), we believe that 
there are a number of possible mechanisms to account for 
the apparent additive effect of inhaled combination therapy 
with ICSs and LABAs in preventing exacerbations and to 
explain the discrepancies observed between the studies. It is 
likely that: (1) the individual drugs were not at the top of 
their dose–response curve for this outcome; (2) they have 
different, and additive, mechanisms of action, which can 
also be linked to the speciﬁ  c compound; or (3) the differ-
ent agents were preventing different types of exacerbation. 
Jones (2004) has highlighted that an operational deﬁ  nition 
based upon a worsening of symptoms and the treatment 
required (moderate exacerbations are those that can be 
treated with oral corticosteroids and/or antibiotics, severe 
exacerbations are those requiring hospital admission) does 
not identify the type of
 exacerbation. This emphasizes again 
the importance for the need of a uniform deﬁ  nition of COPD 
exacerbation for clinical trials in order to reach more solid 
conclusions.
Whatever the case may be, it must be emphasized that 
a treatment regimen with administration of an ICS and 
LABA in a single inhaler prolongs the time to a ﬁ  rst COPD 
exacerbation, compared with treatment with the single 
components in patients with an FEV1 <50% predicted 
(Calverley et al 2003b). Intriguingly, this ﬁ  nding has been 
observed with BFC (Calverley et al 2003b), but not with 
FSC (Calverley et al 2003a). The prolonged time to ﬁ  rst 
exacerbation may delay the deterioration of the disease 
and help maintain health status and patient well-being. It 
is an important outcome because it indicates that following 
aggressive treatment of an acute exacerbation with an oral 
corticosteroid, therapy with an ICS/LABA combination 
may better control the disease than treatment with bron-
chodilator alone. In particular, as highlighted by Calverley 
(2004), combining treatments is certainly something to be 
considered in patients who have reported exacerbations 
on a regular basis but have not yet received ICS or LABA 
therapy in combination, although there are concerns about 
Table 2 Absolute and relative risk reductions for exacerbations of COPD requiring medical intervention with number needed to 
treat in three randomized and double-blind multinational trials 
Treatment      12 month frequency of     Absolute risk   Relative risk   NTT   Reference 
  exacerbation (mean     reduction  reduction 
 rate/patient/year)        (combination 
       vs  LABA)    
   combination  therapy   LABA  only             
Fluticasone/salmeterol   0.97   1.04   0.07   0.067  (6.7%)   14    Calverley et al 
(TRISTAN, n = 1456)             2003a 
Budesonide/formoterol   1.42   1.84   0.42   0.23  (23%)   2.4    Szafranski et al 
(n = 812)             2003 
Budesonide/formoterol   1.38   1.85   0.47   0.25  (25%)   2.1    Calverley et al 
(n = 1002)             2003b 
Data from Cazzola 2006.
Abbreviations: LABA, long-acting ß2-agonist; NNT, number needed to treat.
Table 3 Deﬁ  nitions of COPD exacerbation used in combination 
therapy studies
Study      Deﬁ   nition 
Hanania et al 2003     Deﬁ  ned by treatment, with moderate 
  exacerbations requiring treatment with 
  antibiotics and/or corticosteroids, and 
  severe exacerbations requiring 
 hospitalization) 
Mahler et al 2002    Deﬁ  ned by treatment (mild = increased use 
  of salbutamol; moderate = use of either oral 
  antibiotics and/or corticosteroids; severe =
   hospitalization) 
Calverley et al 2003a   Worsening of COPD symptoms that 
(TRISTAN study)     required treatment with antibiotics, oral 
  corticosteroids, or both 
Szafranski et al 2003     Mild: a day with ≥ 4 inhalations of reliever 
  medication above the mean run-in use; 
  severe: requirement for oral steroids and/or
   antibiotics and/or hospitalization due to 
 respiratory  symptoms 
Calverley et al 2003b    Event requiring medical intervention (oral 
  antibiotics and/or corticosteroids or 
  hospitalization) due to respiratory 
 symptoms International Journal of COPD 2006:1(4) 353
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the increased risk of side-effects and cost of using LABA/
ICS therapy in COPD.
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